Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2024 · fourth_quarter · 4T
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Source: Senate LDA
| DIAMONDBACK DRUGS |
| 24 |
| 2013–2018 |
| CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY) | 12 | 2013–2015 |
| US COMPOUNDING | 11 | 2013–2015 |
| TOWN & COUNTRY COMPOUNDING AND CONSULTING | 9 | 2014–2016 |
| AMERICAN SOCIETY OF ASSN EXECUTIVES | 5 | 1999–2001 |
| ELOTTERY | 5 | 1999–2001 |
| NATL ASSN OF INDUSTRIAL AND OFFICE PROPERTIES | 4 | 1999–2000 |
| PARRY ROMANI ASSOCIATES | 1 | 2018 |
| SOUTHERN CO SERVICES | 1 | 1999 |
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WELLNESS PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: VETERINARY PHARMACIES OF AMERICA, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PRECISION PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WEDGEWOOD VILLAGE PHARMACY, INC. · Firm: ROCK & ASSOCIATES
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Preserving Patient Access to Compounded Medications Act of 2019
Client: WOMEN'S INTERNATIONAL PHARMACY · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
Preserving Patient Access to Compounded Medications Act of 2019
Client: BRAIDWOOD MANAGEMENT, INC. · Firm: ROCK & ASSOCIATES
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2024 · fourth_quarter · 4T
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Legislation relating to regulation of compounding pharmacies.
Appropriations legislation related to FDA and compounding pharmacy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2024 · third_quarter · Q3
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Appropriations legislation related to FDA and compounding pharmacy.
Legislation relating to regulation of compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2024 · third_quarter · Q3
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2024 · second_quarter · Q2
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Legislation relating to regulation of compounding pharmacies.
Appropriations legislation related to FDA and compounding pharmacy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2024 · second_quarter · Q2
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2024 · first_quarter · 1A
Appropriations legislation related to FDA and compounding pharmacy.
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Legislation relating to regulation of compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2024 · first_quarter · 1A
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2023 · fourth_quarter · 4A
Legislation relating to regulation of compounding pharmacies.
Appropriations legislation related to FDA and compounding pharmacy.
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2023 · fourth_quarter · 4A
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2023 · second_quarter · Q2
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2023 · second_quarter · Q2
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2023 · second_quarter · 2T
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2023 · second_quarter · Q2
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Appropriations legislation related to FDA and compounding pharmacy.
Legislation relating to regulation of compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2023 · first_quarter · Q1
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2023 · first_quarter · Q1
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2023 · first_quarter · Q1
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Legislation regulating compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2023 · first_quarter · Q1
Legislation relating to the regulation of compounding pharmacies. No specific legislation at this time.
Appropriations legislation related to FDA and compounding pharmacy.
Legislation relating to regulation of compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2022 · fourth_quarter · Q4
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Issues related to animal drug compounding. No specific legislation yet.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2022 · fourth_quarter · Q4
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Issues related to animal drug compounding and GFI #256.
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2022 · fourth_quarter · Q4
Issues related to the regulation of animal drug compounding and GFI #256.
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2022 · fourth_quarter · Q4
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2022 · third_quarter · Q3
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Issues related to animal drug compounding. No specific legislation yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2022 · third_quarter · Q3
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues related to animal drug compounding and GFI #256.
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2022 · third_quarter · Q3
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Issues related to the regulation of animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2022 · third_quarter · Q3
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2022 · second_quarter · Q2
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Issues related to animal drug compounding. No specific legislation yet.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2022 · second_quarter · Q2
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Issues related to animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2022 · second_quarter · Q2
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Issues related to the regulation of animal drug compounding and GFI #256.
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2022 · second_quarter · Q2
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2022 · first_quarter · Q1
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Issues related to animal drug compounding. No specific legislation yet.
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELLNESS PHARMACY via ROCK & ASSOCIATES
2022 · first_quarter · 1T
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and on the implementation of the MOU under section 503A of the FDCA.
Appropriations and report language related to the funding of FDA as it affects compounding pharmacies.
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2022 · first_quarter · Q1
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues related to animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2022 · first_quarter · Q1
Issues related to the regulation of animal drug compounding and GFI #256.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2022 · first_quarter · Q1
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2021 · fourth_quarter · Q4
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Issues related to animal drug compounding. No specific legislation yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELLNESS PHARMACY via ROCK & ASSOCIATES
2021 · fourth_quarter · Q4
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and on the implementation of the MOU under section 503A of the FDCA.
Appropriations and report language related to the funding of FDA as it affects compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2021 · fourth_quarter · Q4
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues related to animal drug compounding and GFI #256.
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2021 · fourth_quarter · Q4
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Issues related to the regulation of animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2021 · fourth_quarter · Q4
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2021 · third_quarter · Q3
Issues related to animal drug compounding. No specific legislation yet.
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELLNESS PHARMACY via ROCK & ASSOCIATES
2021 · third_quarter · Q3
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Appropriations and report language related to the funding of FDA as it affects compounding pharmacies.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and on the implementation of the MOU under section 503A of the FDCA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2021 · third_quarter · Q3
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Issues related to animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2021 · third_quarter · Q3
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Issues related to the regulation of animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2021 · third_quarter · Q3
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2021 · second_quarter · 2T
Issues related to the NASEM report to the FDA on compounding bioidentical hormones. Issues related to the MOU under 503A of the FDCA.
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Appropriations and report language as it relates to compounding pharmacy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2021 · second_quarter · Q2
Issues related to animal drug compounding. No specific legislation yet.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELLNESS PHARMACY via ROCK & ASSOCIATES
2021 · second_quarter · Q2
Appropriations and report language related to the funding of FDA as it affects compounding pharmacies.
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and on the implementation of the MOU under section 503A of the FDCA.
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2021 · second_quarter · Q2
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Issues related to animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2021 · second_quarter · Q2
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Issues related to the regulation of animal drug compounding and GFI #256.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2021 · second_quarter · Q2
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2021 · first_quarter · Q1
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and issues related to GFI #256 on animal drug compounding.
Issues related to animal drug compounding. No specific legislation yet.
Issues related to Appropriations and report language funding the FDA, specifically as it relates to animal drug compounding. No bill numbers yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELLNESS PHARMACY via ROCK & ASSOCIATES
2021 · first_quarter · Q1
Issues related to the NASEM report to the FDA on compounded bioidentical hormones, and on the implementation of the MOU under section 503A of the FDCA.
Appropriations and report language related to the funding of FDA as it affects compounding pharmacies.
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2021 · first_quarter · Q1
Appropriations and report language as it relates to compounding pharmacy.
Issues related to the federal regulation of compounding pharmacy. No specific legislation at this time.
Issues related to the NASEM report to the FDA on compounding bioidentical hormones. Issues related to the MOU under 503A of the FDCA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2021 · first_quarter · Q1
Issues related to animal drug compounding and GFI #256.
Appropriations and report language of legislation funding the FDA as it relates to animal drug compounding. No specific legislation at this time.
Issues involving the NASEM report to FDA on compounding bioidentical hormones, and issues involving animal drug compounding.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2021 · first_quarter · Q1
Issues related to the NASEM report to FDA on compounded bioidentical hormones.
Issues related to the regulation of animal drug compounding and GFI #256.
Issues related to funding of the FDA for FY2022 as it relates to compounding pharmacy.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2021 · first_quarter · Q1
Appropriations and associated report for funding of the FDA as it affects compounding pharmacies.
Issues pertaining with the report of NASEM on compounded bioidentical hormones,.
Issues related to the federal regulation of compounding pharmacies. No specific legislation to date.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2020 · fourth_quarter · 4A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2020 · fourth_quarter · 4A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2020 · fourth_quarter · 4A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2020 · fourth_quarter · 4A
Appropriations for FY2020. Not specific legislation yet.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2020 · fourth_quarter · 4A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2020 · fourth_quarter · 4A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2020 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2020 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2020 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2020 · fourth_quarter · Q4
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Appropriations for FY2020. Not specific legislation yet.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2020 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2020 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2020 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2020 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2020 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2020 · third_quarter · Q3
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Appropriations for FY2020. Not specific legislation yet.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2020 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2020 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2020 · second_quarter · 2A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2020 · second_quarter · 2A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2020 · second_quarter · 2A
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Appropriations for FY2020. Not specific legislation yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2020 · second_quarter · 2A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2020 · second_quarter · 2A
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2020 · second_quarter · Q2
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
PRECISION PHARMACY via ROCK & ASSOCIATES
2020 · second_quarter · Q2
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2020 · second_quarter · Q2
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2020 · second_quarter · Q2
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Appropriations for FY2020. Not specific legislation yet.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2020 · second_quarter · Q2
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2020 · second_quarter · Q2
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2020 · first_quarter · Q1
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2020 · first_quarter · Q1
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2020 · first_quarter · Q1
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2020 · first_quarter · Q1
Appropriations for FY2020. Not specific legislation yet.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2020 · first_quarter · Q1
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2020 · first_quarter · Q1
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2019 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2019 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WOMEN'S INTERNATIONAL PHARMACY via ROCK & ASSOCIATES
2019 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WEDGEWOOD VILLAGE PHARMACY, INC. via ROCK & ASSOCIATES
2019 · fourth_quarter · Q4
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Appropriations for FY2020. Not specific legislation yet.
H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VETERINARY PHARMACIES OF AMERICA, INC. via ROCK & ASSOCIATES
2019 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
BRAIDWOOD MANAGEMENT, INC. via ROCK & ASSOCIATES
2019 · fourth_quarter · Q4
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PRECISION PHARMACY via ROCK & ASSOCIATES
2019 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.
WELLNESS PHARMACY via ROCK & ASSOCIATES
2019 · third_quarter · Q3
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE